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Purpose of the study
PI-based regimens are rarely used in developing countries
due to the high cost and low availability. We evaluated
characteristics of patients initiating PI-based therapy
according to previous antiretroviral (ARV) exposure; fac-
tors associated with initiating a PI therapy using newer vs.
older PIs; and detectable viral load (VL) following the ini-
tiation of a PI-based regimen.
Methods
This analysis includes all patients initiating a PI-based reg-
imen. ARV exposure was categorised according to the ini-
tiation of PI-based therapy: naïve (no previous ARV), 1st,
2nd, >3rd switches; a switch was defined as starting or
stopping any drug in a regimen. Newer PIs were defined
as those that were approved by the US FDA after January
1, 2000. Detectable VL at 12 months was defined as VL >
400 copies/mL. Characteristics at PI initiation were evalu-
ated. Logistic regression was used to determine factors
associated with initiating a newer PI and detectable VL at
12 months after a PI initiation.
Summary of results
1,106 patients initiated PI-based therapy, [618 (56%)
were naïve to PI-based therapy] and the main reason for a
change to PI was treatment failure (26%). Following PI
initiation, 793 (72%) had VL measurements at 12
months. For multiple logistic regression analysis, switch
patients were less likely to use a newer PI [1st, odds ratio
(OR) = 0.22, p < 0.001; 2nd, OR = 0.12, p < 0.001; and
>3rd switches, OR = 0.14, p < 0.001; vs. naïve]. Being from
a high income country (vs. mid/low income OR = 1.67, p
= 0.005), patent PI (vs. generic PI, OR = 18.64, p < 0.001),
and years from HIV diagnosis to PI initiation (OR = 1.07
per year, p = 0.017) were associated with more use of a
newer PI. Overall, 22% (176) of patients had detectable
VL at 12 months following the PI initiation. Among naïve
patients, the only predictor for detectable VL was baseline
CD4 [CD4 200–350 cells/μL, OR = 0.28, p = 0.001; CD4
> 350 cells/μL, OR = 0.73, p = 0.445; vs. CD4 <200 cells/
μL]. In experienced patients, higher baseline CD4 [CD4
200–350 cells/μL, OR = 0.39, p = 0.024; CD4 > 350 cells/
μL OR = 0.69, p = 0.469; vs. CD4<200 cells/μL] was less
likely to have a detectable VL. Being from a high income
country (vs. mid/low income, OR = 1.80, p = 0.034) was
more likely to associate with detectable VL.
Conclusion
Newer PI-based regimens were prescribed more in high
income countries than in other countries in Asia. Short-
term virological outcomes following PI therapy in our
cohort were good, and were related with CD4 count at
time of initiation.
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